Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis.
暂无分享,去创建一个
P. Górski | D. Pastuszak-Lewandoska | D. Domańska | K. Czarnecka | M. Migdalska-Sęk | A. Antczak | P. Górski | W. Piotrowski | E. Nawrot | J. Kiszałkiewicz | E. Brzeziańska-Lasota | W. J. Piotrowski | J. Kiszałkiewicz | D. Pastuszak-Lewandoska | A. Antczak | M. Migdalska-Sęk | W. Górski | K. H. Czarnecka | D. Domańska | E. Nawrot | E. Brzeziańska-Lasota | W. Górski
[1] A. Fal,et al. [Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods]. , 2011, Pneumonologia i alergologia polska.
[2] T. Sugai,et al. Heterogeneous characteristics of lymphatic microvasculatures associated with pulmonary sarcoid granulomas. , 2013, Annals of the American Thoracic Society.
[3] N. Siafakas,et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. , 2006, Chest.
[4] K. Müller,et al. Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis , 1998, Virchows Archiv.
[5] D. Ziora,et al. [Proangiogenic cytokines (bFGF and VEGF) in BALF from two different lung segments examined by high resolution computed tomography (HRCT) in patients with sarcoidosis]. , 2000, Pneumonologia i alergologia polska.
[6] F. Bonella,et al. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease , 2009, Respiration.
[7] G. Semenza,et al. Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .
[8] W. Młynarski,et al. Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis. , 2014, Polskie Archiwum Medycyny Wewnetrznej.
[9] U. Demkow,et al. Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function , 2010, European journal of medical research.
[10] 陶仲为. Sarcoidosis , 2009 .
[11] G. Hunninghake,et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[12] A. Prasse,et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[13] J. Tidball,et al. Mechanical loading regulates expression of talin and its mRNA, which are concentrated at myotendinous junctions. , 1998, American journal of physiology. Cell physiology.
[14] A. Lazarus. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. , 2009, Disease-a-month : DM.
[15] G. Semenza,et al. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. , 1998, The American journal of physiology.
[16] D. Pastuszak-Lewandoska,et al. TGF-β and SMADs mRNA Expression in Pulmonary Sarcoidosis. , 2015, Advances in experimental medicine and biology.
[17] D. Sheppard,et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.
[18] G. Hunninghake,et al. ATS/ERS/WASOG statement on sarcoidosis , 1999 .
[19] Y. Fukuchi,et al. Serum Vascular Endothelial Growth Factor as a Possible Prognostic Indicator in Sarcoidosis , 2003, Lung.
[20] M. Déry,et al. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. , 2005, The international journal of biochemistry & cell biology.
[21] A. Karameris,et al. Expression of Hypoxia-Inducible Factor (HIF)-1a-Vascular Endothelial Growth Factor (VEGF)-Inhibitory Growth Factor (ING)-4- axis in sarcoidosis patients , 2012, BMC Research Notes.
[22] G. Semenza,et al. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. , 2011, American journal of respiratory and critical care medicine.
[23] M. Frid,et al. Hypoxia-induced Pulmonary Vascular Remodeling Cellular and Molecular Mechanisms Reviews , 2022 .
[24] R. Pedeux,et al. The ING tumor suppressor genes: status in human tumors. , 2014, Cancer letters.
[25] D. Spandidos,et al. Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study , 2010, Clinical & developmental immunology.